Here’s whether Guardant Health, Inc. Common Stock (GH) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+9.11% over 10 days); strong 1-year return of +159.5%; 3-month momentum positive (+37.7%). Concerns: RSI 76 — overbought, elevated pullback risk. Currently 6.5% off its 52-week high. Score: +5/7.
GH is in a confirmed uptrend, trading above both its 50-day ($98.71) and 200-day ($90.92) moving averages. With an RSI of 75.6, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +159.5% compares to +24.4% for SPY (beat the market by 135.1%).
$10,000 invested 1 year ago→ $25,947 today
vs. S&P 500 (SPY) — same period beat market by 135.1%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($90.92)
✓Above 50-day MA ($98.71)
!RSI(14) neutral zone (30–70) — currently 75.6
✓Positive return (+159.5%)
✓Within 10% of period high (−6.5%)
Period Range $125.61
$40.36$134.28
RSI (14) 75.6
0 · OversoldOverbought · 100
Key Metrics
Price$125.61
Period Return+159.5%
Period High$134.28
Period Low$40.36
Drawdown−6.5%
MA-50$98.71
MA-200$90.92
RSI (14)75.6
Avg Volume (30d)2.3M
vs. SPYbeat by 135.1%
Return Rank#126 of 1245
Trend Signals
Price is above the 200-day moving average ($90.92)